Asset
AXATILIMAB
SYNDAX PHARMACEUTICALS INC. COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03238027 | phase1 | completed | 2017-09-01 | 2020-11-20 | Syndax Pharmaceuticals | A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors |
| NCT03604692 | phase1_2 | completed | 2018-11-01 | 2022-08-12 | Syndax Pharmaceuticals | A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD |
| NCT04415073 | phase2 | terminated | 2020-05-30 | 2020-07-13 | Syndax Pharmaceuticals | A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19 |
| NCT04710576 | phase2 | recruiting | 2021-03-04 | 2023-04-07 | Syndax Pharmaceuticals | A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) |
| NCT06132256 | phase2 | active_not_recruiting | 2023-12-11 | 2026-09-01 | Syndax Pharmaceuticals | MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF) |
FDA applications (0)
This company has no applications containing this asset.